Last reviewed · How we verify
Pegylated Liposomal Doxorubicin (PLD) (pegylated-liposomal-doxorubicin-pld)
Pegylated Liposomal Doxorubicin (PLD) (generic name: pegylated-liposomal-doxorubicin-pld) is a RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in drug developed by Pfizer Inc.. It is currently in discontinued development.
RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in
Pegylated liposomal doxorubicin (PLD) was a chemotherapy drug developed by Pfizer Inc. that used a liposomal delivery system to encapsulate doxorubicin. The drug's mechanism of action and specific indications are unknown as it was discontinued.
At a glance
| Generic name | pegylated-liposomal-doxorubicin-pld |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
Pipeline indications
- Ovarian Cancer — discontinued
Common side effects
Key clinical trials
- A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Li (Phase 3)
- Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovar (Phase 1/2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated Liposomal Doxorubicin (PLD) CI brief — competitive landscape report
- Pegylated Liposomal Doxorubicin (PLD) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Pegylated Liposomal Doxorubicin (PLD)
What is Pegylated Liposomal Doxorubicin (PLD)?
How does Pegylated Liposomal Doxorubicin (PLD) work?
Who makes Pegylated Liposomal Doxorubicin (PLD)?
What is the generic name of Pegylated Liposomal Doxorubicin (PLD)?
What drug class is Pegylated Liposomal Doxorubicin (PLD) in?
What development phase is Pegylated Liposomal Doxorubicin (PLD) in?
Related
- Drug class: All RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Compare: Pegylated Liposomal Doxorubicin (PLD) vs similar drugs
- Pricing: Pegylated Liposomal Doxorubicin (PLD) cost, discount & access